NCT01732822

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 13,885 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 50 Years – 130 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.

Detailed description

A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)

Conditions

• Peripheral Artery Disease

Interventions

Type	Name	Description
DRUG	Ticagrelor	Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
DRUG	Clopidogrel	Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets

Timeline

• Start date: 2012-12-04
• Primary completion: 2016-09-26
• Completion: 2016-09-26
• First posted: 2012-11-26
• Last updated: 2017-10-30
• Results posted: 2017-10-30

Locations

776 sites across 28 countries: United States, Argentina, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Hungary, Italy, Japan, Mexico, Netherlands, Philippines, Poland, Romania, Russia, Slovakia, South Korea, Spain, Sweden, Thailand, Turkey (Türkiye), Ukraine, United Kingdom, Vietnam